CATCo Regulatory News (CAT)

7 Mar 2005 15:47

Cambridge Antibody Tech Group PLC07 March 2005 The following replaces the previous shareholding announcement released today at14.45 p.m. under RNS Reference 4185J. The figures set out in the Schedule 11Announcement for John Aston at numbers 15 and 16 are revised. SCHEDULE 11 NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS 1) Name of companyCambridge Antibody Technology 2) Name of directorPeter Chambre 3) Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of anon-beneficial interest or in the case of an individual holder if it is aholding of that person's spouse or children under the age of 18 or in respect ofa non-beneficial interestAs in 2 Above 4) Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them (if notified)As in 2 above 5) Please state whether notification relates to a person(s) connected with the Director named in 2 above and identify the connected person(s)As in 2 above 6) Please state the nature of the transaction. For PEP transactions please indicate whether general/single co PEP and if discretionary/non discretionaryMarket purchase of 3,541 shares to be held as "Invested Shares" underExecutive Incentive Plan 7) Number of shares/amount of stock acquired3,541 8) Percentage of issued class0.007% 9) Number of shares/amount of stock disposedNone 10) Percentage of issued classNone 11) Class of securityOrdinary 10 pence shares 12) Price per share £7.06 13) Date of transaction4 March 2005 14) Date company informed4 March 2005 15) Total holding following this notification26,090 16) Total percentage holding of issued class following this notification0.05% If a director has been granted options by the company please complete thefollowing boxes 17) Date of grant4 March 2005 18) Period during which or date on which exercisable4 March 2008 to 3 March 2011 19) Total amount paid (if any) for grant of the optionNil 20) Description of shares or debentures involved: class, number10,623 Ordinary 10 pence shares 21) Exercise price (if fixed at time of grant) or indication that price is to be fixed at time of exercise10 pence per share subject to Award 22) Total number of shares or debentures over which options held following this notification343,566 of which:206,974 are Options under Company Share Option Plan 92,510 are Restricted Share Awards under Executive Incentive Plan 44,082 are Matching Shares under Executive Incentive Plan 23) Any additional informationAwards granted under the Executive Incentive Plan are subject to performanceconditions 24) Name of contact and telephone number for queriesJustin Hoskins: 01223 898589 25) Name and signature of authorised company official responsible for making this notificationDiane MellettDate of Notification 7 March 2005 SCHEDULE 11 NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS 1) Name of companyCambridge Antibody Technology 2) Name of directorDiane Mellett 3) Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of anon-beneficial interest or in the case of an individual holder if it is aholding of that person's spouse or children under the age of 18 or in respect ofa non-beneficial interestAs in 2 Above 4) Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them (if notified)As in 2 above 5) Please state whether notification relates to a person(s) connected with the Director named in 2 above and identify the connected person(s)As in 2 above 6) Please state the nature of the transaction. For PEP transactions please indicate whether general/single co PEP and if discretionary/non discretionaryMarket purchase of 495 shares to be held as "Invested Shares" underExecutive Incentive Plan 7) Number of shares/amount of stock acquired495 8) Percentage of issued class0.001% 9) Number of shares/amount of stock disposedNone 10) Percentage of issued classNone 11) Class of securityOrdinary 10 pence shares 12) Price per share £7.06 13) Date of transaction4 March 2005 14) Date company informed4 March 2005 15) Total holding following this notification15,062 16) Total percentage holding of issued class following this notification0.029% If a director has been granted options by the company please complete thefollowing boxes 17) Date of grant4 March 2005 18) Period during which or date on which exercisable4 March 2008 to 3 March 2011 19) Total amount paid (if any) for grant of the optionNil 20) Description of shares or debentures involved: class, number1,485 Ordinary 10 pence shares 21) Exercise price (if fixed at time of grant) or indication that price is to be fixed at time of exercise10 pence per share subject to Award 22) Total number of shares or debentures over which options held following this notification112,786 of which:76,874 are Options under Company Share Option Plan31,901 are Restricted Share Awards under Executive Incentive Plan 4,011 are Matching Shares under Executive Incentive Plan 23) Any additional informationAwards granted under the Executive Incentive Plan are subject to performanceconditions 24) Name of contact and telephone number for queriesJustin Hoskins: 01223 898589 25) Name and signature of authorised company official responsible for making this notificationDiane MellettDate of Notification 7 March 2005 SCHEDULE 11 NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS 1) Name of companyCambridge Antibody Technology 2) Name of directorJohn Aston 3) Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of anon-beneficial interest or in the case of an individual holder if it is aholding of that person's spouse or children under the age of 18 or in respect ofa non-beneficial interestAs in 2 Above 4) Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them (if notified)As in 2 above 5) Please state whether notification relates to a person(s) connected with the Director named in 2 above and identify the connected person(s)As in 2 above 6) Please state the nature of the transaction. For PEP transactions please indicate whether general/single co PEP and if discretionary/non discretionaryMarket purchase of 3,541 shares to be held as "Invested Shares" underExecutive Incentive Plan at £7.06 Exercise of options over 25,000 shares at £2.87 and 9,964 shares at £2.42 ofwhich 22,273 shares were sold at £7.00 and 12,691 were retained. 7) Number of shares/amount of stock acquired38,505 8) Percentage of issued class0.075% 9) Number of shares/amount of stock disposed22,273 10) Percentage of issued class0.043% 11) Class of securityOrdinary 10 pence shares 12) Price per share See 6 above 13) Date of transaction4 March 2005 14) Date company informed4 March 2005 15) Total holding following this notification59,962 16) Total percentage holding of issued class following this notification0.12% If a director has been granted options by the company please complete thefollowing boxes 17) Date of grant4 March 2005 18) Period during which or date on which exercisable4 March 2008 to 3 March 2011 19) Total amount paid (if any) for grant of the optionNil 20) Description of shares or debentures involved: class, number10,623 Ordinary 10 pence shares 21) Exercise price (if fixed at time of grant) or indication that price is to be fixed at time of exercise10 pence per share subject to Award 22) Total number of shares or debentures over which options held following this notification125,733 of which:51,087 are Options under Company Share Option Plan57,765 are Restricted Share Awards under Executive Incentive Plan16,881 are Matching Shares under Executive Incentive Plan 23) Any additional informationAwards granted under the Executive Incentive Plan are subject to performanceconditions 24) Name of contact and telephone number for queriesJustin Hoskins: 01223 898589 25) Name and signature of authorised company official responsible for making this notificationDiane MellettDate of Notification 7 March 2005 This information is provided by RNS The company news service from the London Stock Exchange